Teva Pharmaceutical Industries Limited (TEVA)

NYSE: TEVA · USD

$39.9

-0.50 (-1.2%)· Recorded snapshot

Market cap	46.5B
Revenue (ttm)	17.3B
Net income (ttm)	706M
EPS (ttm)	$0.60
Shares out	1.2B
P/E (trailing)	66.3x
P/E (forward)	14.2x
Volume	3,355,055
Beta	0.82

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 17.3B
Net income (ttm): 706M
EPS (ttm): $0.60
P/E (trailing): 66.3x
P/E (forward): 14.2x
Market cap: 46.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E14.2

P25 n/aP50 n/aP75 n/a

Trailing P/E66.3

P25 n/aP50 n/aP75 n/a

ROE9.7

P25 n/aP50 n/aP75 n/a

ROIC15.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TEVA indicators

Market & fundamental data

Available fields

255

Groups with data

Currency

USD

Showing 255 of 255 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000818686
Company name	Teva Pharmaceutical Industries Limited
Country	Israel
Country code	US
Earnings date	2026-11-03
Earnings time	bmo
Employees	33,950
Employees change	-2,880
Employees growth	-7.82%
Enterprise value	$59.7B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1901
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	IL0006290147
Last 10-K release date	2026-02-03
Last earnings date	2026-07-29
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$46.5B
Market cap category	Large-Cap
Next earnings date	2026-11-03
Options	Yes
Price	$39.90
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TEVA
Website	https://www.tevapharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	1.51%
EV/Earnings	84.81x
EV/EBIT	18.25x
EV/EBITDA	14.03x
EV/FCF	44.45x
EV/Sales	3.46x
FCF / EV yield	2.25%
FCF yield	2.89%
Forward EV/Sales	3.57x
Forward P/E	14.16x
Forward P/S	2.78x
Graham number	9.49057
Graham upside	-76.29%
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	39.55x
P/(OCF - SBC) ratio	26.96x
P/B ratio	6.07x
P/E ratio	66.31x
P/FCF ratio	34.62x
P/OCF ratio	24.57x
P/S ratio	2.69x
PEG ratio	1.96x
Price/EBITDA ratio	10.93x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	18.94%
EBITDA margin	24.65%
Effective tax rate	1.67%
FCF margin	7.78%
Gross margin	52.46%
Operating margin	18.94%
Pretax margin	4.15%
Profit margin	4.08%
Profit per employee	$20,795
Profitable years	1
Revenue per employee	$510,015
ROA	5.13%
ROA (5Y)	4.67%
ROCE	13.55%
ROE	9.69%
ROE (5Y)	-7.19%
ROIC	15.21%
ROIC (5Y)	12.12%
SBC / revenue	0.97%
Tax / revenue	0.07%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth 10Y	-8.71%
EPS growth years	1
FCF growth	51.35%
FCF growth (Q)	134.35%
FCF growth 3Y	4.72%
Gross profit growth	10.14%
Gross profit growth (Q)	2.43%
Gross profit growth 3Y	10.04%
Gross profit growth 5Y	3.49%
Net income growth years	1
OCF growth	36.55%
OCF growth (Q)	81.06%
OCF growth 10Y	-9.32%
OCF growth 3Y	3.84%
OCF growth 5Y	33.3%
Operating income growth	-6.31%
Operating income growth (Q)	-81.32%
Operating income growth 3Y	9.75%
Operating income growth 5Y	2.42%
Revenue growth	4.13%
Revenue growth (Q)	-0.81%
Revenue growth (QoQ)	4.02%
Revenue growth 10Y	-1.21%
Revenue growth 3Y	4.86%
Revenue growth 5Y	1.19%
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-551M
Depreciation and amortization	$988M
EBIT	$3.3B
EBITDA	$4.3B
EPS	$0.60
FCF per share	$1.16
Financing cash flow	$-401M
Free cash flow	$1.3B
Free cash flow minus SBC	$1.2B
Gross profit	$9.1B
Income taxes	$12M
Investing cash flow	$37M
Net borrowing	$-474M
Net cash flow	$1.5B
Net income	$706M
Operating cash flow minus SBC	$1.7B
Operating income	$3.3B
Revenue	$17.3B
Stock-based compensation	$168M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.68
Book value per share	$6.65
Debt / EBITDA	3.84
Debt / equity	2.18
Debt / FCF	12.54
Goodwill	$15.8B
Interest coverage	3.81
Long-term assets	$26.1B
Long-term liabilities	$16.5B
Net cash (debt)	$-13.2B
Net cash / market cap	-28.39%
Net debt / EBITDA	3.1
Net debt / equity	1.71
Net debt / FCF	9.83
Piotroski F-Score	7
Property, plant and equipment	$4.3B
Shareholders' equity	$7.8B
Tangible book value	$-11.5B
Tangible book value per share	$-9.90
Total assets	$39.9B
Total cash	$3.7B
Total debt	$16.9B
Total liabilities	$32.1B
WACC	7.75%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.43
Current assets	$13.8B
Current liabilities	$15.6B
Current ratio	0.88
Inventory turnover	2.45
Net working capital	$-1B
Quick ratio	0.46
Working capital	$-1.9B
Working capital turnover	-30.73

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.24%
Dividend growth (10Y)	8.28%
Dividend growth (3Y)	-14.39%
Dividend growth (5Y)	-2.11%
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$0.07
Shareholder yield	-2.24%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-7.25%
10Y return CAGR	-0.39%
10Y total return	-3.86%
150-day SMA	$35.17
15Y price change	-4.78%
15Y return CAGR	0.64%
15Y total return	10.08%
1D price change	-1.23%
1M price change	2.12%
1M total return	2.12%
1W price change	-2.03%
1W total return	-2.03%
1Y price change	104.08%
1Y return CAGR	104.18%
1Y total return	104.08%
20-day SMA	$40.28
200-day SMA	$34.49
20Y price change	20.36%
20Y return CAGR	1.95%
20Y total return	46.99%
3M price change	28.76%
3M total return	28.76%
3Y price change	392.86%
3Y return CAGR	70.16%
3Y total return	392.86%
50-day SMA	$38.90
50-day SMA vs 200-day SMA	50over200
52-week high	$42.02
52-week high date	2026-10-09
52-week low	$19.23
52-week low date	2025-10-28
5Y price change	348.15%
5Y return CAGR	34.99%
5Y total return	348.15%
6M price change	28.02%
6M total return	28.02%
All-time high	$72.31
All-time high date	2015-07-28
All-time low	$0.30
All-time low date	1988-02-03
Average true range (ATR)	$1.11
Average volume	6M
Beta (1Y)	0.04
Beta (2Y)	-0.56
Beta (5Y)	0.82
Change from 52-week high	-5.06%
Change from 52-week low	107.46%
Change from all-time high	-44.65%
Change from all-time low	13,379.29%
Change from open	0.36%
Day's gap	-1.58%
Dollar volume	$133.8M
High price	$40.49
Low price	$39.50
Monthly RSI	76.18
Open price	$39.75
Position in 52-week range	39.9%
Premarket change	-1.66%
Premarket close	$40.39
Premarket price	$39.72
Premarket volume	65.7K
Previous close	$40.39
Price vs 150-day SMA	13.78%
Price vs 20-day SMA	-0.65%
Price vs 200-day SMA	16.04%
Price vs 50-day SMA	2.88%
Relative volume	0.56
RSI	51.33
Sharpe ratio	1.92
Sharpe ratio (3Y)	1.4
Sharpe ratio (5Y)	0.76
Sortino ratio	4.17
Sortino ratio (3Y)	2.68
Sortino ratio (5Y)	1.43
Volume	3.4M
Weekly RSI	64.04
YTD price change	28.23%
YTD total return	28.23%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.1B
Float percentage	93.43%
Shares change (QoQ)	-1.19%
Shares change (YoY)	2.24%
Shares held by insiders	0.43%
Shares held by institutions	74.35%
Shares outstanding	1.2B
Short % of shares	2.57%
Short ratio	9.1 days

Deeper analysis on TEVA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TEVA report

Is a complete TEVA research report available?

No complete published report is available for Teva Pharmaceutical Industries Limited (TEVA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Teva Pharmaceutical Industries Limited (TEVA)

Price

Financial snapshot

Fair-value bridge

Latest news · TEVA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TEVA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TEVA

Frequently asked questions